Analyst Upgrades and Price Targets for Semtech, Fidelity National Info, Freeport-McMoRan, Adial Pharmaceuticals, and Celsius Holdings.

Semtech Corporation (NASDAQ:SMTC) was upgraded from Perform to Outperform by Oppenheimer analyst Rick Schafer, with a price target of $81. Other upgrades include Fidelity National Information Services (NYSE:FIS) from Neutral to Buy by UBS analyst Timothy Chiodo, Freeport-McMoRan Inc. (NYSE:FCX) from Neutral to Buy by B of A Securities analyst Lawson Winder, Adial Pharmaceuticals (NASDAQ:ADIL) from Hold to Buy by Maxim Group analyst Jason McCarthy, and Celsius Holdings (NASDAQ:CELH) from Equal-Weight to Overweight by Morgan Stanley analyst Eric Serotta.

Semiconductor giant Semtech Corporation (NASDAQ:SMTC) saw its shares jump nearly 5.5% during early trading hours on Tuesday as Oppenheimer analyst Rick Schafer upgraded the company to Outperform from Perform. The analyst set a price target of $81, citing the acceleration of Active Copper Cable (ACC) adoption beginning in the fourth quarter. Schafer estimated that ACC could account for 70-80% of Semtech's growth, highlighting its potential as a top driver of the firm's expansion Semtech jumps over 5% on Oppenheimer upgrade to Outperform^[1].

Fidelity National Information Services (NYSE:FIS), another beneficiary of analyst upgrades, saw its stock upgraded from Neutral to Buy by UBS analyst Timothy Chiodo. The analyst set a price target of $82.00, noting that the stock appears undervalued according to InvestingPro analysis. The upgrade comes after FIS shares declined approximately 20% year-to-date, partly due to recent selling pressure associated with tax loss harvesting. UBS cited several factors supporting its more positive outlook, including prospects for earnings of $6.25+ in fiscal year 2026 and improved margin expansion Fidelity National Information Services stock rating upgraded to Buy by UBS^[2].

Freeport-McMoRan Inc. (NYSE:FCX) was also upgraded from Neutral to Buy by B of A Securities analyst Lawson Winder. The analyst set a price target of $48.50, noting that the company's recent earnings beat and strong revenue growth provided a solid foundation for future performance. Other upgrades include Adial Pharmaceuticals (NASDAQ:ADIL) from Hold to Buy by Maxim Group analyst Jason McCarthy and Celsius Holdings (NASDAQ:CELH) from Equal-Weight to Overweight by Morgan Stanley analyst Eric Serotta Trivium Point Advisory LLC Has $3.62 Million Stock Position in Freeport-McMoRan Inc. $FCX^[3].

These upgrades reflect a growing optimism among analysts about the future prospects of these companies. As the markets continue to evolve, investors should closely monitor these upgrades and the companies' performance to make informed investment decisions.